Pharmaceuticals

Daewoong Pharmaceutical Unveils 'Innovative Drug Delivery Technologies' in Milan--From World's First Microneedle Therapy to Once-a-Month Obesity Treatment

MILAN, Oct. 10, 2024 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Chang-jae Lee) announced on the 9th that they will present their cutting-edge drug delivery technologies, including the world's first microneedle-based drugs, at 'CPHI Worldwide 2024'—the world's largest phar...

2024-10-10 06:16 4047

New INTREPID Alliance Antiviral Landscape Report Highlights Urgent Need to Bolster R&D Pipeline in Support of Global Pandemic Preparedness Efforts

Current mpox outbreak underscores gaps in access to medical countermeasures to help mitigate the severity of future outbreaks CAMBRIDGE, Mass., Oct. 9, 2024 /PRNewswire/ -- Today, the INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating antiviral tr...

2024-10-09 19:00 1996

The CDE has Granted Breakthrough Therapy Designation to LBL-024, a Bispecific Antibody that Targets PD-L1 and 4-1BB, Developed by Leads Biolabs, for the Treatment of Extrapulmonary Neuroendocrine Carcinoma.

NANJING, China, Oct. 9, 2024 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs") announced that Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation to LBL-024, an anti-PD-L1/4-1BB bispecific antibody indepe...

2024-10-09 13:38 3159

Seegene and Werfen Finalize Partnership Agreement on Technology-Sharing Initiative

* Werfen, a worldwide leader in specialized diagnostics, becomes the first European company to finalize the partnership agreement to join Seegene's technology-sharing initiative * The two companies will co-establish a NewCo in Spain to serve as a strategic hub inEurope, accelerating global ex...

2024-10-08 21:00 3734

LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance

GAITHERSBURG, Md., Oct. 8, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for in...

2024-10-08 20:30 4539

Pierre Fabre Laboratories and Scorpion Therapeutics Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-241/STX-241, a Mutant-Selective Inhibitor Intended To Treat Locally Advanced or Metastatic Non-Small Cell Lung Cancer

PFL-241/STX-241 is a highly selective, and potentially best-in-class fourth generation epidermal growth factor receptor ("EGFR") inhibitor One of two EGFR programs being developed with Scorpion Therapeutics CASTRES, France and BOSTON, Oct. 8, 2024 /PRNewswire/ -- Pierre Fabre Laboratories, a glo...

2024-10-08 20:00 2798

Registrational Phase III Studies of APG-2449 Cleared by China CDE for the Treatment of Patients with NSCLC

ROCKVILLE, Md. and SUZHOU, China, Oct. 8, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that APG-2449, a FAK/ALK...

2024-10-08 10:26 3642

Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer

SAN FRANCISCO and SUZHOU, China, Oct. 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic...

2024-10-08 08:00 3962

Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy

MELBOURNE, Australia, Oct. 8, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Australian Therapeutic Goods Administration (TGA) has approved the use of Illuccix® (kit for the preparation of68Ga-PSMA-11[1] injection) to select patients for...

2024-10-08 04:00 3270

The U.S. Fish and Wildlife Service Rejects Petition to List Long-Tailed Macaques Under the Endangered Species Act

WASHINGTON, Oct. 8, 2024 /PRNewswire/ -- On October 7, 2024, the U.S. Fish and Wildlife Service ("USFWS" or "the Service") declined to accept a petition filed by People for the Ethical Treatment of Animals (PETA) and other advocacy groups to list long-tailed macaque ("LTM") monkeys (Macaca fascic...

2024-10-08 03:31 3783

GBI Biomanufacturing and Allterum Therapeutics Announce Strategic Collaboration to Manufacture Therapeutic Antibody for Clinical Trials

PLANTATION, Florida and HOUSTON, Texas, Oct. 8, 2024 /PRNewswire/ -- GBI Biomanufacturing, a leading Contract Development and Manufacturing Organization (CDMO), andAllterum Therapeutics, a Fannin-Founded Company, are pleased to announce a manufacturing partnership to advance Allterum's lead candi...

2024-10-08 00:00 2077

NTC Launches Imperial, the new eye drops product line on THE PATIENT'S SIDE

MILAN, Oct. 7, 2024 /PRNewswire/ -- NTC, an international pharmaceutical company headquartered inMilan, Italy, announced today to have embraced a strategic partnership with Silgan Dispensing Systems, a global leading supplier of dispensing solutions in healthcare to commercialize a set of new NTC...

2024-10-07 18:00 2763

Antengene to Present Results from Three Programs at the 2024 SITC Annual Meeting

SHANGHAI and HONG KONG, Oct. 5, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cance...

2024-10-07 13:14 3248

Clarivate in partnership with Abiquifi Announces Annual Summit LATAM Agenda

Top industry leaders to explore AI, data, strategic partnerships, and innovation opportunities inLatin America at premier Life Sciences event LONDON, Oct. 4, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) a leading global provider of transformative intelligence, today announced the full agenda ...

2024-10-04 15:00 3098

Sirnaomics Has Been Subscribed for 17,527,696 Subscription Shares, New Capital Injection to Promote Business Growth and Development

HONG KONG, GERMANTOWN, Md., and SUZHOU, China,, Oct. 4, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or " Sirnaomics"; stock code: 2257.HK), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutic...

2024-10-04 13:03 8021

ABL Bio Announces Clinical Collaboration to Evaluate ABL103 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors

- MSD will supply KEYTRUDA to be evaluated in combination with ABL Bio's ABL103 in a Phase1b/2 clinical trial SEONGNAM, South Korea, Oct. 4, 2024 /PRNewswire/ -- ABL Bio (CEO Sang Hoon Lee ), a company specializing in bispecific antibodies, today announced that it has entered into a clinical tria...

2024-10-04 12:40 4047

First Patient Dosed in Phase II 'CA-NINE' Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery

MELBOURNE, Australia, Oct. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase II trial exploring the clinical utility of Telix's first-in-class investigational PET[1] agent, TLX250-CDx (89Zr-girentu...

2024-10-04 04:00 4126

IBC launches RadSep, Inc.: Best-in-class, highly selective separations using Molecular Recognition Technology™ (MRT™) for production of critical radioisotopes essential to cancer therapies

* Best-in-class, highly selective separations technology for the radiopharmaceuticals industry * Exhibitor at the European Association of Nuclear Medicine (EANM) Congress in Hamburg, Germany 20-23 October 2024 at Booth S14 (Exhibition Hall 3) * Over 36 years of experience with first generatio...

2024-10-03 22:15 2390

Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries

-  Non-exclusive voluntary license agreement enables the manufacture and distribution of lenacapavir for HIV prevention and treatment of heavily treatment-experienced patients with multi drug-resistant HIV HYDERABAD, India, Oct. 2, 2024 /PRNewswire/ -- Hetero, India's leading pharmaceutical comp...

2024-10-02 22:53 4887

OPTEL and Worximity Join Forces to Boost Line Performance with Real-Time OEE Solutions

QUÉBEC CITY, Oct. 1, 2024 /PRNewswire/ -- OPTEL, a global leader in traceability and vision systems, and Worximity, a leading provider of OEE and real-time production monitoring, are partnering to help manufacturers boost operational efficiency.

2024-10-01 19:00 3427
1 ... 62636465666768 ... 184